Recovery of sinus rhythm by tafamidis in patients with wild-type transthyretin amyloid cardiomyopathy with atrial arrhythmias.
Yoshitaka IsotaniEisuke AmiyaJunichi IshidaMasato IshizukaMasaru HatanoKoki NakanishiMasao DaimonIssei KomuroPublished in: Oxford medical case reports (2022)
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening infiltrative disease in elderly patients. Atrial arrhythmias (AAr) are common in patients with ATTR-CM. However, AAr treatment in these patients is challenging. In this case, a patient diagnosed with wild-type ATTR-CM suffered atrial fibrillation (AF) for ~1 year, according to the data of his self-monitoring and regular electrocardiogram. This AF reverted to normal sinus rhythm a few months after the initiation of tafamidis without administering an antiarrhythmic drug. Tafamidis may be beneficial as alternative antiarrhythmic therapy in patients with ATTR-CM.
Keyphrases
- wild type
- atrial fibrillation
- catheter ablation
- left atrial
- heart failure
- oral anticoagulants
- left atrial appendage
- direct oral anticoagulants
- end stage renal disease
- ejection fraction
- percutaneous coronary intervention
- newly diagnosed
- chronic kidney disease
- case report
- big data
- heart rate
- stem cells
- acute coronary syndrome
- machine learning
- artificial intelligence
- venous thromboembolism
- replacement therapy